Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2026—Cybersecurity and image management are key concerns for laboratories adopting digital pathology and AI. While cloud-based systems offer enhanced security and scalability, onboarding new vendors and instruments remains challenging due to stringent security requirements and potential vulnerabilities.
February 2026—CAP TODAY publisher Bob McGonnagle spoke on Dec. 2, 2025 with Steve Swartzell and Scott Johnston of ELITechGroup. McGonnagle’s questions and their answers follow. A few of the questions came from the roundtable audience and are identified as such.
Bob McGonnagle: Steve, how long have you been with ELITech and what is your background in molecular diagnostics?
Steve Swartzell: I am director of customer experience and have been with ELITechGroup for 22 years. My background is in microbiology. I started as a research scientist in R&D and I was an application specialist working directly with customers. I have many years of lab experience as well. Now I oversee all the field activities for ELITechGroup MDx in the U.S. Continue reading …
Watch the full conversation:
This roundtable discussion is sponsored by ELITechGroup.
January 2026—The Association for Diagnostics and Laboratory Medicine released new guidance discouraging clot-based testing in patients receiving direct oral anticoagulants (DOACs).
November 2025—A roundtable discussion on laboratory information systems (LIS) highlighted the challenges labs face in meeting increasing demands with limited resources. The conversation emphasized the need for improved interoperability, automation, and flexibility in LIS to address complex testing workflows and workforce shortages.
November 2025—CAP TODAY publisher Bob McGonnagle spoke on Oct. 1, 2025 with Sarah Stewart of Telcor, which sells laboratory revenue cycle management software and services, and Jeanette Gray and Scott Rupnow of Pathology Associates of San Antonio and Pathology Reference Laboratory.
Bob McGonnagle: Jeanette Gray, tell us about your laboratory.
Jeanette Gray, vice president of revenue and payer relations, Pathology Associates of San Antonio and Pathology Reference Laboratory: We are a physician-owned practice in San Antonio and we operate a laboratory that does primarily anatomic pathology and women’s health testing. We have about 20-plus pathologists on staff. I joined the practice in July. Continue reading …
Watch the full conversation:
This roundtable discussion is sponsored by Telcor.
October 2025—Glass or digital, onsite or remote—and what the rules are for the latter. That’s what Compass Group lab leaders talked about with CAP TODAY publisher Bob McGonnagle when they met online on Sept. 2. Here’s a glimpse into their digital pathology journeys. The Compass Group is an organization of not-for-profit IDN system laboratory leaders who collaborate to identify and share best practices and strategies.
August 2025—With cuts to government programs underway or on the way, how are laboratory budgets affected? CAP TODAY publisher Bob McGonnagle asked members of the Compass Group what the impact has been as of July 1, when the group met online. Also up: how one lab is gearing up to close two patient care gaps and using a Costco approach to do so.
August 2025—CAP TODAY publisher Bob McGonnagle spoke on May 14 with Jessica Van Allen, PhD, technical support lead for ZeptoMetrix, and Meghan Starolis, MS, PhD, HCLD(ABB), senior science director for infectious diseases at Quest Diagnostics, Chantilly, Va.
Bob McGonnagle: Jessica Van Allen, I’d like to talk about some of the hot topics in molecular infectious disease testing, and you mentioned in our discussions offline that viral load testing for transplant viruses is becoming ever more important in the field. Can you make a few remarks about that?
Jessica Van Allen, PhD (ZeptoMetrix): There’s testing that is done using laboratory-developed tests and testing performed using FDA-cleared assays. Those are the two big buckets of testing in the labs of our customers. Meghan and I attended a conference recently at which a couple of the speakers talked about viral load testing for common transplant viruses—EBV, CMV, VZV, some adenoviruses. We’ve been playing in that field for a long time in terms of molecular controls for viruses, so they’re products we’ve had on the shelf. Continue reading …
Watch the full conversation:
This roundtable discussion is sponsored by ZeptoMetrix.
July 2025—What’s new from Roche, Hologic, and Siemens Healthineers, and how they aim to lighten for labs the burden of the workforce shortage. CAP TODAY publisher Bob McGonnagle spoke about these and other things with three company representatives in an online roundtable, and Stan Schofield, Compass Group managing principal, told them what three questions companies must answer to get a laboratory’s business. Their June 2 conversation follows.
June 2025—Chemistry and immunoassay analyzers—the customer input that shapes their development and the laboratory acquisition process and timeline. That and more, including the IT obstacles and solutions, were the focus of a roundtable, led by CAP TODAY publisher Bob McGonnagle. He spoke with Moira Larsen, MD, MBA, of MedStar Health; Joe Baker of Baylor Scott & White; and representatives of Beckman Coulter, Roche, and Siemens Healthineers. Read about their April 15 online conversation.
